PCI Pharma to manufacture AusCann’s first medicinal cannabis product for chronic pain

Medical cannabis company AusCann has chosen PCI Pharma to manufacture and release its first product designed to help treat chronic pain.

PCI Pharma will produce and release AusCann’s solid hard shell capsules for the treatment of chronic pain. The capsules, scheduled to be realised in 2019, are intended to help the estimated 1.9 million Australians who suffer from chronic pain. The product line is also set to be made available internationally and for clinical studies.

Elaine Darby, managing director of AusCann, said: “AusCann elected to work with PCI Pharma due to their significant experience in providing manufacturing services of solid dose potent products to high standards of safety and quality. This allows AusCann to bring its first hard shell capsules into the chronic pain market as quickly as possible, while continuing to focus on the development of our second generation cannabinoid pharmaceutical products.”